Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based study

S. Y. Yang, Yea-Huei Kao, M. Y. Chong, Y. H. Yang, W. H. Chang, C. S. Lai

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

To compare the prevalence of extrapyramidal syndrome (EPS) between the first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), the co-prescribing rate of anti-Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5-year study period. Among the SGAs, quetiapine had the lowest crude co-prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the FGAs, thioridazine and loxapine had the lowest (60.99%) and highest rates (96.35%), respectively. The rankings of the co-prescribing rate of APDs among antipsychotics, in increasing order, were quetiapine, clozapine, olanzapine, thioridazine, zotepine, chlorpromazine, risperidone, sulpiride, clotiapine, flupentixol, haloperidol, zuclopentixol, trifluoperazine, and loxapine. The results indicate that the risk of EPS appears to be lower in SGAs than in FGAs; however, the considerably high rate of EPS in some of the newer generation of antipsychotics warrants clinical attention.

Original languageEnglish
Pages (from-to)586-594
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume81
Issue number4
DOIs
Publication statusPublished - 2007 May 10

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based study'. Together they form a unique fingerprint.

  • Cite this